TransMedics Group, Inc. (NASDAQ:TMDX) VP Sells $37,965.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) VP John F. Carey sold 1,500 shares of TransMedics Group stock in a transaction that occurred on Wednesday, May 4th. The stock was sold at an average price of $25.31, for a total transaction of $37,965.00. Following the completion of the transaction, the vice president now owns 379 shares of the company’s stock, valued at approximately $9,592.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of TMDX opened at $27.59 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.47 and a current ratio of 5.11. The stock has a market capitalization of $771.91 million, a P/E ratio of -16.23 and a beta of 1.79. The company’s fifty day moving average is $22.94 and its two-hundred day moving average is $21.29. TransMedics Group, Inc. has a 1 year low of $10.00 and a 1 year high of $35.37.

TransMedics Group (NASDAQ:TMDXGet Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). TransMedics Group had a negative net margin of 119.88% and a negative return on equity of 59.72%. During the same period in the previous year, the company posted ($0.29) EPS. Sell-side analysts predict that TransMedics Group, Inc. will post -1.38 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of TransMedics Group by 2.9% during the 4th quarter. BlackRock Inc. now owns 1,900,939 shares of the company’s stock worth $36,422,000 after purchasing an additional 53,571 shares in the last quarter. Sandhill Capital Partners LLC boosted its position in shares of TransMedics Group by 25.4% during the 4th quarter. Sandhill Capital Partners LLC now owns 1,805,518 shares of the company’s stock worth $34,594,000 after purchasing an additional 365,473 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of TransMedics Group by 6.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,624,216 shares of the company’s stock worth $53,745,000 after purchasing an additional 105,095 shares in the last quarter. State Street Corp boosted its position in shares of TransMedics Group by 2.1% during the 4th quarter. State Street Corp now owns 818,440 shares of the company’s stock worth $15,681,000 after purchasing an additional 17,169 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its position in shares of TransMedics Group by 9.6% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 512,284 shares of the company’s stock worth $13,801,000 after purchasing an additional 45,000 shares in the last quarter. 71.75% of the stock is currently owned by institutional investors.

A number of brokerages recently issued reports on TMDX. JPMorgan Chase & Co. decreased their price target on shares of TransMedics Group from $20.00 to $12.00 in a research note on Thursday, February 24th. Zacks Investment Research downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Wednesday, April 27th. Morgan Stanley cut their price objective on shares of TransMedics Group from $22.00 to $15.00 and set an “equal weight” rating on the stock in a report on Friday, February 25th. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, March 17th. Finally, Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $39.00 to $46.00 in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Hold” and an average price target of $32.29.

About TransMedics Group (Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

See Also

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.